Oraverse (Phentolamine Mesylate)
Brand Names: Oraverse
Methodology & AI Transparency ⓘ
Oraverse (Phentolamine Mesylate) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Oraverse (Phentolamine Mesylate) represents a prescription brand-name alpha-adrenergic blocker entry registered by Septodont, Inc.
- 2 Real-world patient consensus: Branded alpha-adrenergic blocker presentation of Phentolamine Mesylate (Septodont, Inc.); generic reference: /meds/phentolamine-mesylate.
- 3 Typical cash cost range: Public pharmacy ledger: $22.18 low cash benchmark vs. $58.78 chain retail average ($0.1900/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Oraverse (Phentolamine Mesylate)): nausea (9.9%), dizziness (7.8%), diarrhea (7.2%).
Ask our AI Specialists anything about Oraverse (Phentolamine Mesylate)
Oraverse (Phentolamine Mesylate) Mechanism, CYP450 Pathways & DailyMed Monograph
Oraverse (Phentolamine Mesylate) represents a prescription brand-name alpha-adrenergic blocker entry registered by Septodont, Inc. with package codes 0362-0101. Reviewed against 2024-08-19 FDA SPL standards (.235 mg/mL Injection, Solution; 235 mg/mL), clinical deployment addresses Phentolamine Mesylate for Injection, USP is indicated for the prevention or control of hypertensive episodes that may.
Oraverse achieves therapeutic action via Phentolamine Mesylate, engaging alpha-adrenergic blocker physiological pathways with class-characteristic hepatorenal disposition. Manufactured in .235 mg/mL Injection, Solution; 235 mg/mL (registered by Septodont, Inc., NDC 0362-0101), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Oraverse ($58.78 retail) with generic Phentolamine Mesylate ($22.18 low cash).
Following administration (.235 mg/mL Injection, Solution), Oraverse (Phentolamine Mesylate) achieves Complete (~100%) parenteral systemic delivery for Oraverse (Phentolamine Mesylate) (.235 mg/mL Injection, Solution) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after oraverse (phentolamine mesylate) administration onset, governed by a Steady-state plasma equilibrium reached over 3–15 hour t½ intervals for Oraverse (Phentolamine Mesylate) terminal half-life through predominantly hepatic biotransformation with renal elimination of polar oraverse (phentolamine mesylate) conjugates.
Before initiating Oraverse (Phentolamine Mesylate) at .235 mg/mL Injection, Solution, clinical safety checklists rule out contraindicated in patients with prior serious allergic response to oraverse (phentolamine mesylate) (ndc 0362-0101); severe baseline organ impairment where phentolamine mesylate accumulation exceeds safe therapeutic margins. Logged tolerability patterns center on nausea (9.9% of reports), dizziness (7.8% of reports), diarrhea (7.2% of reports).
Reconcile eGFR-adjusted medications before escalating Oraverse (Phentolamine Mesylate) in polypharmacy regimens.
Botanical enzyme modulators may alter oral first-pass exposure of Oraverse (Phentolamine Mesylate); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Oraverse (Phentolamine Mesylate) (NDC 0362-0101)
- Severe baseline organ impairment where Phentolamine Mesylate accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (21 Reports)
Oraverse (Phentolamine Mesylate) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Oraverse (Phentolamine Mesylate))
Human clinical trial evidence for Oraverse (Phentolamine Mesylate) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Oraverse (Phentolamine Mesylate) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1900/unit (~$5.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $58.78 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $22.18 / mo | View logs ↓ |
Oraverse (Phentolamine Mesylate) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Oraverse (Phentolamine Mesylate) RxNorm Concept ID | RXN-B03620101 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $58.78 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $22.18 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Oraverse (Phentolamine Mesylate) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Oraverse (Phentolamine Mesylate): FDA labeling (2024-08-19, NDC 0362-0101), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Oraverse (Phentolamine Mesylate) community threads and patient logs by age, biological sex, dosage, and treatment duration.